Want to see AU:BOT full AI Analyst Report?
Top Page
Botanix Pharmaceuticals Limited
(Sydney:BOT)
Select Model
Select Model
Rating:48Neutral
Price Target:
AU$0.02
▲(5.00% Upside)
Action:Reiterated
Date:07/28/26
The score is held down primarily by very weak financial performance (large ongoing losses and heavy cash burn) and a weak longer-term price trend (below the 100/200-day averages). These negatives are partially offset by an earnings-call picture of strong Sofdra commercial traction and identifiable margin catalysts, though funding and supply-chain execution risks remain key.
Positive Factors
Commercial traction for Sofdra
Sofdra's rapid prescription and revenue ramp demonstrates durable product-market fit and physician adoption. Sustained high uptake supports predictable recurring revenue, scale benefits for marketing ROI and payer negotiations, and underpins long-term revenue growth as coverage expands.
Negative Factors
Severe cash burn and operating losses
Persistent, large negative operating and free cash flows represent a structural financing pressure. Continued heavy losses consume reserves, force repeated capital raises or dilution, and constrain strategic flexibility; sustained negative cash flow threatens long-term viability absent clear path to positive cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial traction for Sofdra
Sofdra's rapid prescription and revenue ramp demonstrates durable product-market fit and physician adoption. Sustained high uptake supports predictable recurring revenue, scale benefits for marketing ROI and payer negotiations, and underpins long-term revenue growth as coverage expands.
Read all positive factors
Botanix Pharmaceuticals Limited (BOT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$51.95M
Dividend YieldN/A
Average Volume (3M)8.47M
Price to Earnings (P/E)―
Beta (1Y)0.86
Revenue Growth2086.71%
EPS Growth-116.20%
CountryAU
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.05
Shares Outstanding2,734,312,700
10 Day Avg. Volume7,344,780
30 Day Avg. Volume8,473,310
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)7.26
Price to Sales (P/S)101.98
P/FCF Ratio-7.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.57Price Target Upside2750.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$73.83M
Botanix Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
Botanix Pharmaceuticals Limited, an Australian enterprise, is dedicated to the discovery and advancement of novel dermatological and antimicrobial therapeutic agents. The company's central mission involves pioneering innovative treatments for wide...
How the Company Makes Money
null...
Botanix Pharmaceuticals Limited Earnings Call Summary
Earnings Call Date:Feb 27, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Aug 28, 2026
Earnings Call Sentiment Neutral
The call conveyed strong commercial momentum — rapid prescription growth, meaningful revenue ramp, a high‑performing fulfillment platform (fill rates ~2.5x industry), positive physician adoption signals (90% expect to increase prescribing) and an attractive IP runway to 2040. Counterbalancing this progress are sizeable operating losses (adjusted EBITDA loss $26.1M; loss before tax $33.2M), material near‑term API purchase obligations and reliance on a partially‑completed capital raise and a single API supplier. Management has identified clear catalysts (alternate API supplier to cut COGS 25%–40%, platform scalability, and $45M committed raise) but execution and funding are key near‑term risks. Overall, the call was upbeat on commercial execution but sober about cash, supply and funding needs.Positive Updates
Rapid prescription and revenue growth
62,500 prescriptions shipped in the first 11 months post‑launch; 45,800 prescriptions in H1 FY2026 vs 16,800 in the prior half (171% increase). Net revenue rose from $5.1M in the second half of FY2025 to $16.2M in H1 FY2026 (219% increase). Total revenue for H1 FY2026 was $16.5M (versus $0.346M prior corresponding period).
Negative Updates
Substantial operating losses and cash burn
Adjusted EBITDA loss for H1 FY2026 was $26.1M and loss before tax was $33.2M. Direct operating expenses totaled $36.6M (including $24.7M sales & marketing and $7M internal employee costs). Company closed the period with $31.6M cash and equivalents, creating sensitivity to continuing funding and execution.
Read all updates
Q2-2026 Updates
Positive
Negative
Rapid prescription and revenue growth
62,500 prescriptions shipped in the first 11 months post‑launch; 45,800 prescriptions in H1 FY2026 vs 16,800 in the prior half (171% increase). Net revenue rose from $5.1M in the second half of FY2025 to $16.2M in H1 FY2026 (219% increase). Total revenue for H1 FY2026 was $16.5M (versus $0.346M prior corresponding period).
Read all positive updates
Company Guidance
Management guided that Botanix will scale Sofdra and its SendRx fulfillment platform while pursuing cost and supply improvements: since launch Sofdra has shipped 62,500 prescriptions (first 11 months) generating almost $100M gross revenue and $21.2M net revenue, and in H1 FY26 prescriptions rose 171% to 45,800 (from 16,800) with net revenue up 219% to $16.2M (total revenue $16.5M incl. royalties); fill/adherence metrics exceed industry benchmarks (~2.5x), the U.S. sales force is 50 reps (expanded Oct‑2025), cash was $31.6M at period end, adjusted EBITDA loss was $26.1M and loss before tax $33.2M, with materials $6.0M, sales & marketing $24.7M, employee costs $7.0M and G&A $3.2M. They have firm commitments for a $45M raise ($14.9M received) with proceeds allocated roughly $12M API/manufacturing, $4M alternate‑API setup, $13.5M marketing, $13M operating/working capital and $2.5M fees, are negotiating to defer near‑term API purchases (Mar/Apr 2026 and Jan 2027), and expect an alternate API to cut COGS 25–40% and improve gross‑to‑net toward ~30–40%; Sofdra’s IP runs to 2040 and the TAM is ~10M patients (≈3.7M actively seeking treatment), with management expecting revenue growth to outpace costs as adoption and payer coverage expand.Botanix Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
55
Neutral
Cash Flow
26
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 21.92M | 5.79M | 601.82K | 914.97K | 2.75M | 6.89M |
| Gross Profit | -25.91M | 2.02M | -6.12M | -3.05M | -7.54M | 315.80K |
| EBITDA | -82.23M | -80.65M | -15.25M | -12.63M | -15.74M | -10.06M |
| Net Income | -88.70M | -86.40M | -13.87M | -9.15M | -13.17M | -3.33M |
Balance Sheet | ||||||
| Total Assets | 98.57M | 129.10M | 112.46M | 24.84M | 14.04M | 21.95M |
| Cash, Cash Equivalents and Short-Term Investments | 31.61M | 64.97M | 79.31M | 10.25M | 7.29M | 21.55M |
| Total Debt | 30.67M | 32.51M | 0.00 | 0.00 | 122.41K | 259.32K |
| Total Liabilities | 44.58M | 47.80M | 3.73M | 1.88M | 5.89M | 1.15M |
| Stockholders Equity | 54.00M | 81.30M | 108.73M | 22.95M | 8.15M | 20.80M |
Cash Flow | ||||||
| Free Cash Flow | -80.86M | -78.87M | -26.13M | -19.13M | -14.11M | -2.98M |
| Operating Cash Flow | -80.66M | -78.58M | -8.13M | -12.07M | -11.18M | -2.97M |
| Investing Cash Flow | -637.53K | -1.05M | -18.00M | -7.05M | -2.92M | -8.28K |
| Financing Cash Flow | 64.77M | 65.36M | 95.10M | 22.03M | -152.41K | -125.50K |
Botanix Pharmaceuticals Limited Technical Analysis
Negative
0.02
Price Trends
0.02
Negative
0.03
Negative
0.07
Negative
Market Momentum
<0.01
Positive
46.68
Neutral
-32.22
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BOT, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 46.68 is Neutral, neither overbought nor oversold. The STOCH value of -32.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:BOT.
Botanix Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | AU$456.88M | 13.94 | 13.29% | 0.50% | 5.17% | -16.14% | |
52 Neutral | AU$5.95M | -1.56 | 80.84% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$357.79M | -97.40 | -15.96% | ― | 364.97% | 74.58% | |
48 Neutral | AU$51.95M | -0.41 | -131.13% | ― | 2086.71% | -116.20% | |
41 Neutral | AU$113.04M | -3.27 | 279.21% | ― | ― | -37.23% | |
40 Underperform | AU$5.90M | -1.72 | -211.88% | ― | 250.37% | 71.29% |
* Healthcare Sector Average
AU:BOT
Botanix Pharmaceuticals Limited
0.02
-0.13
-86.90%
AU:ACR
Acrux
0.01
>-0.01
-37.50%
AU:CUV
Clinuvel Pharmaceuticals
9.06
-3.16
-25.86%
AU:SPL
Starpharma Holdings Limited
0.75
0.66
706.45%
AU:ZLD
Zelira Therapeutics
0.50
0.09
21.95%
AU:RCE
Recce Pharmaceuticals Ltd.
0.37
>-0.01
-1.33%
Botanix Pharmaceuticals Limited Corporate Events
Botanix boosts Sofdra sales, tightens costs and fortifies IP as cash position strengthens
Jul 26, 2026
Botanix Pharmaceuticals reported strong growth for the June quarter, with Sofdra prescriptions rising 25% to 33,358 and June setting a record monthly shipment of 12,895. Gross sales climbed to $46.7 million and unaudited net revenue rose 45% to $1...
Botanix Seeks ASX Quotation for 10.3 Million New Shares
May 25, 2026
Botanix Pharmaceuticals has applied for quotation on the ASX of 10.3 million new ordinary fully paid shares, with an issue date of 22 May 2026, expanding the number of securities available for trading under its BOT code. The additional shares, iss...
Botanix Securities Lapse Trims Potential Share Dilution
May 21, 2026
Botanix Pharmaceuticals has notified the market of the lapse of a series of options and performance rights, resulting in the cessation of several classes of securities. A total of 8,819,840 options and performance rights expired on 19 May 2026 aft...
Botanix Sets Stricter Securities Trading Rules to Bolster Market Confidence
May 8, 2026
Botanix Pharmaceuticals has formalized a securities trading policy that applies to its directors, officers, employees, consultants and contractors globally, setting clear rules for dealing in company securities. The policy aims to uphold high stan...
Botanix Shifts Registered Office to Melbourne as It Advances Hyperhidrosis Drug
May 6, 2026
Botanix Pharmaceuticals has relocated its registered office, principal place of business and postal address to Level 23, Tower 5, Collins Square, 727 Collins Street, Melbourne, Victoria, effective immediately. The move centralises the company̵...
Botanix Taps Veteran Executive Paul Seaback as Chief Operating Officer
May 3, 2026
Botanix Pharmaceuticals has promoted Paul Seaback to Chief Operating Officer, expanding his remit from Chief Technical Officer to overseeing day-to-day operations and strategic initiatives across the business. With more than 30 years of experience...
Botanix issues investor update with detailed disclaimers and risk caveats
Apr 29, 2026
Botanix Pharmaceuticals has issued an investor update presentation dated 29 April 2026, outlining general information about the company and the context for potential investors. The document emphasises that it is a summary of information, should be...
Botanix builds Sofdra momentum, fortifies balance sheet and supply chain
Apr 29, 2026
Botanix reported continued growth in Sofdra prescriptions in the March quarter, with total prescriptions rising 5% to 26,684 and March delivering a record month as the U.S. hyperhidrosis market moves into the seasonally stronger summer period. Des...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.